Stem Cell Treatment for Crohn’s Disease: Supporting Gut Healing and Daily Comfort

In this episode, we explore how stem cell therapy may support people living with Crohn’s disease by calming inflammation, aiding tissue repair, and improving quality of life.

You’ll learn:

• What stem cell therapy is and how it complements standard Crohn’s treatments
• How mesenchymal and hematopoietic stem cells may help regulate immune activity and support gut healing
• Why therapy focuses on realistic goals like fewer flares, reduced symptoms, and better daily comfort
• Who may benefit from cell-based support, and how careful screening ensures safety
• What to expect during treatment, from cell preparation and IV or local administration to ongoing monitoring

While there is no cure for Crohn’s disease, structured stem cell programs can enhance supportive care, improve day-to-day function, and strengthen the overall treatment plan when coordinated with your gastroenterology team.

Blog Link: Stem Cell Treatment For Crohn’s Disease

Transcript

SPEAKER_01 0:00

Welcome to the Sorona Cell Podcast. So I want you to imagine your body's immune system as like a high-tech home security alarm.

SPEAKER_00 0:08

Aaron Powell Okay. I like this analogy.

SPEAKER_01 0:10

Trevor Burrus, Right. Now imagine that alarm gets tripped by um basically a phantom burglar.

SPEAKER_00 0:14

Trevor Burrus, Jr.: A threat that isn't actually there.

SPEAKER_01 0:16

Trevor Burrus Exactly. The sirens are blaring, the indoor sprinklers go off, and then the police show up with literal sledgehammers and they just start tearing down your own living room walls trying to find this nonexistent threat.

SPEAKER_00 0:27

Aaron Powell And the worst part is they don't stop.

SPEAKER_01 0:30

They don't. They keep smashing the drywall day after day, month after month. And that relentless, structural, uh-friendly fire is essentially the daily painful reality of Crohn's disease.

SPEAKER_00 0:43

Trevor Burrus, Jr.: It really is. It's devastating.

SPEAKER_01 0:45

Yeah. And look, if you or someone you love is navigating this condition, you know exactly what I'm talking about. You live it. And you also probably know that when you go online looking for advanced answers, you just get hit with this tidal wave of dense medical jargon.

SPEAKER_00 0:57

Aaron Powell Oh, the jargon is overwhelming.

SPEAKER_01 0:58

Trevor Burrus, Jr.: Or worse, right, flashy, totally unregulated clinics making these impossible promises about miracle cures.

SPEAKER_00 1:05

Aaron Powell Yeah. It is a profoundly difficult landscape for a patient to navigate. Because when you are dealing with a disease that fundamentally disrupts your ability to, you know, digest food or absorb nutrients or even just live comfortably, the stakes are incredibly high.

SPEAKER_01 1:21

Aaron Powell Absolutely.

SPEAKER_00 1:22

So our baseline for this deep dive is to basically cut entirely through that noise. We are looking strictly at the clinical documented science of cell-based care for Crohn's disease.

SPEAKER_01 1:33

Aaron Powell Right, the real science.

SPEAKER_00 1:34

Exactly. We're going to examine what regenerative medicine can actually do, what it absolutely cannot do, and uh why a highly structured, medically supervised approach is really the only responsible way to explore these therapies.

SPEAKER_01 1:47

Aaron Powell Which brings us to our mission today. We are unpacking a really fascinating stack of sources detailing stem cell therapy for Crohn's, specifically looking at the science-led approach of Cyrocell.

SPEAKER_00 1:56

Yes, the regenerative medicine center based out of Kuala Lumpur.

SPEAKER_01 1:59

Right, in Malaysia. But um, before we get into how these advanced therapies actually attempt to intervene, we have to look closely at the battlefield itself, the gut.

SPEAKER_00 2:07

We do. You have to understand the mechanics of the damage first.

SPEAKER_01 2:11

Right, because most of you listening already know that Crohn's is an inflammatory bowel disease and that it's basically an autoimmune misfire. But the actual structural damage is what makes it so incredibly difficult to treat, right?

SPEAKER_00 2:24

Yeah. I mean the defining characteristic of Crohn's is that it can affect literally any part of the gastrointestinal tract, from the mouth all the way down to the colon and the peryannal area.

SPEAKER_01 2:34

Any part of it.

SPEAKER_00 2:35

Any part. And the core mechanical issue is driven by these overactive immune cells, specifically uh certain types of T cells.

SPEAKER_01 2:43

The sledgehammers in our analogy.

SPEAKER_00 2:45

Exactly, the sledgehammers. Instead of recognizing that the gut is safe and healthy, these T cells continuously infiltrate the lining of the intestines. And they release these things called inflammatory cytokines.

SPEAKER_01 2:56

Which are like chemical alarm signals.

SPEAKER_00 2:58

Yeah, it's chemical signals that basically tell the body, hey, keep this area inflamed, keep it swollen. So over time, that constant grinding inflammation erodes the tissue, and that leads to deep ulcers.

SPEAKER_01 3:09

Okay, let's unpack this. Because the sources highlight two major, really severe complications that arise from that continuous tissue erosion, fistulas and strictures.

SPEAKER_00 3:20

Right.

SPEAKER_01 3:20

And look, a fistula just sounds particularly brutal. It's essentially an abnormal tunnel, right, that forms between the intestine and another organ, or even out to the skin.

SPEAKER_00 3:31

Yeah, it's awful. And it's actually the body's it's this misguided attempt to manage the severe inflammation.

SPEAKER_01 3:37

Wait, the body does it on purpose?

SPEAKER_00 3:39

Well, sort of. When an ulcer burns deeply enough through the intestinal wall, the body tries to heal it or drain the infection. But because the environment is so chaotic and inflamed, it ends up building a destructive pathway, a tunnel drilling right through healthy tissue. Yeah. And perianal fiftulas are incredibly common in severe Crohn's. And they are notoriously stubborn. I mean, they are incredibly difficult to close with standard medications. They cause severe pain, chronic drainage, and they just drastically lower a patient's quality of life.

SPEAKER_01 4:09

It sounds like a nightmare. And then on the flip side, you have strictures, which is essentially the exact opposite problem.

SPEAKER_00 4:14

Right. The opposite mechanical problem.

SPEAKER_01 4:16

Yeah. Instead of a tunnel opening up, the tissue thickens from all those constant cycles of like ulceration and scarring. So it creates this narrowed, rigid area in the intestines.

SPEAKER_00 4:25

Like a severe kink in a garden hose.

SPEAKER_01 4:27

Exactly. A kink that slows down or completely blocks the movement of food, which creates an entirely new set of really painful blockages.

SPEAKER_00 4:37

Aaron Ross Powell And both of these complications drastically raise the risk of a patient needing major open bowel resection surgery, which is obviously something patients want to avoid. Right. And if we connect this back to the bigger picture of standard medical care, it really explains why patients eventually seek out alternative therapies.

SPEAKER_01 4:56

Aaron Ross Powell Because standard care has limits.

SPEAKER_00 4:58

Exactly. Standard interventions like steroids, immunomodulators, and biologics, they're designed to chemically suppress that faulty alarm system to forcefully quiet down the immune system. And look, for many people, these drugs are absolute lifesavers. They work they do work for a lot of people.

SPEAKER_01 5:15

But the sources are really clear that a significant portion of patients become refractory, meaning, you know, the drugs just stop working.

SPEAKER_00 5:22

The alarm keeps ringing despite the medications.

SPEAKER_01 5:25

Right. Or the side effects of just totally suppressing your entire immune system become unbearable. So the patient is left looking for a different way to intervene. And here's where it gets really interesting.

SPEAKER_00 5:37

The stem cells.

SPEAKER_01 5:38

Yeah. Because when standard suppressants fail, patients start Googling stem cells. But I have to admit, my own understanding of stem cells was completely warped by pop science.

SPEAKER_00 5:48

Almost everyone's is.

SPEAKER_01 5:49

Right. I always pictured them as like the ultimate cellular construction workers. Like you inject them into the gut, they grab a little hard hat, and they just start rapidly multiplying to build you a brand new shiny intestine from scratch.

SPEAKER_00 6:02

Yeah, and demystifying that exact misconception is crucial. Stem cells do not act as a quick painkiller.

SPEAKER_01 6:08

Yeah.

SPEAKER_00 6:08

And they absolutely do not build a brand new intestine.

SPEAKER_01 6:11

So no hard hats.

SPEAKER_00 6:13

No hard hats. If you put them into an inflamed gut, they don't suddenly turn into intestinal lining. That's not how it works. In the clinical studies for Crohn's disease, there are primarily two distinct types of stem cells being utilized, and neither of them are laying bricks.

SPEAKER_01 6:28

Okay, so what are the two types?

SPEAKER_00 6:30

First, we have mesenchymal stem cells. You'll hear them called MSCs.

SPEAKER_01 6:33

MSCs, got it.

SPEAKER_00 6:34

Right. And these are usually sourced from donated tissue, like the umbilical cord.

SPEAKER_01 6:38

And the second type.

SPEAKER_00 6:39

The second type are hematopoietic stem cells. These are typically sourced directly from the patient's own bone marrow where they're mobilized into their bloodstream. And these are used for a very severe, intense immune reset strategy.

SPEAKER_01 6:54

Okay, so if neither of these are acting like construction workers, what is the actual biological mechanism here? Because my main takeaway from the research is that MSCS, the first type you mentioned, they act much more like highly specialized site managers.

SPEAKER_00 7:08

Yes, that is a great way to put it.

SPEAKER_01 7:09

Because if we go back to our analogy of the police tearing down the living room walls with sledge hammers, the MSCs step onto that chaotic, inflamed construction site of the gut. And instead of picking up a hammer, they start issuing orders.

SPEAKER_00 7:23

Exactly.

SPEAKER_01 7:24

They release these chemical signals that actively tell the panicked T cells to just stand down, turn off the destructive inflammation, and then they hand out the correct biochemical blueprints to the body's existing tissue cells so those native cells can start repairing the ulcers correctly.

SPEAKER_00 7:43

That is the precise mechanism. The medical term for this signaling is immune modulation.

SPEAKER_01 7:48

Immune modulation.

SPEAKER_00 7:49

Right. Mesenchymal stem cells are incredibly reactive to their environment. So when they detect high levels of inflammation, they actually secrete specific anti-inflammatory proteins and growth factors.

SPEAKER_01 7:59

So they're responding to the chaos.

SPEAKER_00 8:01

Exactly. They don't replace the tissue, they fundamentally alter the microenvironment of the gut, they downregulate the aggressive immune cells, and they upregulate the body's natural regulatory cells. The whole goal is to break that cycle of chronic inflammation and provide local healing support, particularly in those really hard-to-treat areas like the fistulas we talked about.

SPEAKER_01 8:22

But you know, theoretical biology is one thing. If you've had Crohn's for 15 years, you really don't care what works in a petri dish in a lab somewhere.

SPEAKER_00 8:30

No, you want to know if it works in a human.

SPEAKER_01 8:32

Exactly. You want to know if this actually works in a living, breathing human body.

SPEAKER_00 8:37

Which brings us to the clinical evidence in the sources.

SPEAKER_01 8:40

And what's fascinating here is that we actually have robust landmark human trials that define exactly where these therapies fit. Right. The sources highlight two major studies that take very, very different approaches. The first is the AUASTIC trial, which was supported by the University of Nottingham.

SPEAKER_00 8:57

Okay, the AASTIC trial.

SPEAKER_01 8:59

Right. And this trial explored autologous hematopoietic stem cell transplantation for severe treatment-resistant Crohn's.

SPEAKER_00 9:07

Okay, wait. Autologous meaning the cells are harvested from the patient's own body. Right. Right. They extracted the patient's own bone marrow or blood stem cells. Yeah. But um, the procedure itself is what makes this so intense. Because the goal wasn't just to calm the immune system down.

SPEAKER_01 9:22

What was it?

SPEAKER_00 9:23

The goal was to completely obliterate it and start over.

SPEAKER_01 9:26

Oh wow. It sounds like taking a computer that's like severely infected with a virus, completely wiping the hard drive and reinstalling the whole operating system from scratch.

SPEAKER_00 9:36

That is functionally exactly what they did. The patients in this trial underwent high-intensity chemotherapy conditioning.

SPEAKER_01 9:42

Chemotherapy for Crohn's.

SPEAKER_00 9:44

Yes, to completely wipe out their faulty immune system. And then those harvested stem cells were re-infused to basically rescue the body and rebuild a new, hopefully non-reactive immune system. That is intense. It's incredibly complex. And have a very high risk route. There were very real severe safety concerns and adverse events in the trial because I mean you are leaving the patient entirely without an immune system for a period of time.

SPEAKER_01 10:08

Right. They have no defenses.

SPEAKER_00 10:09

Exactly. So it taught the medical field that this kind of extreme immune reboot is not just a casual option. It is reserved only for the absolute most severe cases, and it requires really meticulous patient selection.

SPEAKER_01 10:23

Yeah, that sounds terrifying, frankly. It's a massive physical toll on the body. Which honestly makes the alternative approach using those site manager MSCEs seem incredibly appealing.

SPEAKER_00 10:34

Much more approachable, yes.

SPEAKER_01 10:35

So tell me about the other trial our sources covered.

SPEAKER_00 10:38

So the second major study was the Admeyer CD trial. This was linked with KULuven in Belgium.

SPEAKER_01 10:43

Okay.

SPEAKER_00 10:44

And this was a phase three randomized double-blind study.

SPEAKER_01 10:47

Which is the gold standard, right?

SPEAKER_00 10:49

Absolutely. They evaluated allogenetic meaning donor-derived mesenchymal stem cell therapy. And importantly, they specifically targeted complex periodal fistulas in Crohn's patients, which, as we discussed, are just notoriously stubborn.

SPEAKER_01 11:04

Right. And because it's a phase three study, we are talking about a large group of actual patients comparing the stem cell intervention directly against a placebo to see if it actually, you know, moves the needle.

SPEAKER_00 11:14

Yes. And the results were highly significant. They found that patients receiving the MSC product had significantly higher combined remission rates at the 24-week mark.

SPEAKER_01 11:24

Wow.

SPEAKER_00 11:24

And by remission you mean meaning the fistulas physically closed and stopped draining. Compared to the control group, who only received the standard surgical preparation at a placebo.

SPEAKER_01 11:34

That's incredible.

SPEAKER_00 11:35

It is. The MSC's successfully modulated the local immune response enough to allow the body to finally heal those abnormal tunnels.

SPEAKER_01 11:45

I mean, that is a massive quality of life victory for those patients. Just huge. But um, I do want to point out that the sources drill into one specific kind of unglamorous reality repeatedly. We really have to set realistic expectations here.

SPEAKER_00 11:59

I do.

SPEAKER_01 12:00

Even with these successful trials, there's no proven cure for Crohn's today. Even if someone achieves depermission with MSCs, Crohn's is still a chronic condition. It can always return.

SPEAKER_00 12:10

Right. And setting those realistic clinical goals is perhaps the most important part of this entire medical discussion. The objective of stem cell therapy for an inflammatory bowel disease is not some magical one and done cure.

SPEAKER_01 12:21

It's not a silver bullet.

SPEAKER_00 12:22

No. The realistic goals are reducing the frequency and the severity of flares, lowering the overall symptom burden, closing specific stubborn fistulas, and helping patients reduce their reliance on harsh, repeated courses of steroids. Right. It is about shifting the baseline of the disease to give the patient their daily function back.

SPEAKER_01 12:43

So knowing that the science requires that level of like really careful patient selection and seeing the intense risks involved in trials like ASTIC, a glaring problem emerges for the patient today.

SPEAKER_00 12:55

The clinics.

SPEAKER_01 12:56

Yes. If you decide to pursue this, how do you avoid the unregulated clinics? Because honestly, if you search for stem cell treatments online right now, you are flooded with places offering to cure everything, from Crohn's to baldness with a single injection in, like a strip mall?

SPEAKER_00 13:11

It's scary. The sheer volume of predatory clinics is exactly why structured ethical standards matter so much. And our sources focus on a clinic called Sarona Cell, located in Kuala Lumpur, Malaysia, which was basically built specifically to address this gap.

SPEAKER_01 13:25

To do it right.

SPEAKER_00 13:26

Exactly. They serve local Malaysian patients, obviously. But they also draw a really large international base, frequently patients from Australia and the Middle East who are actively seeking out that heavily regulated, medically supervised environment.

SPEAKER_01 13:39

Even their name is interesting to me. The sources mention Sirona is named after a Celtic goddess of health and protection. Right. And it sets a very specific tone, I think, prioritizing safe, protective, science-led care over those wild quick fix promises we were just talking about.

SPEAKER_00 13:56

It does.

SPEAKER_01 13:57

But let's actually dig into the science of their safety boundaries.

SPEAKER_00 14:00

Yeah.

SPEAKER_01 14:01

Because the sources throw out a lot of acronyms regarding how they operate.

SPEAKER_00 14:04

They do. The jargon is dense, but it's really the only way to verify safety. So Severonicelle strictly uses ethically sourced umbilical cord-derived cells. Okay. Specifically, early passage Wharton's Jelly MSEs.

SPEAKER_01 14:17

Wharton's Jelly.

SPEAKER_00 14:18

Yeah, Wharton's Jelly is the gelatinous connective tissue inside the umbilical cord. And it is incredibly rich in potent young mesenchemal stem cells.

SPEAKER_01 14:28

Oh, interesting. And what does early passage mean?

SPEAKER_00 14:30

Early passage means these cells haven't been forcefully multiplied in a lab so many times that they lose their therapeutic signaling power or become genetically unstable. They're fresh and potent. And they are obtained from healthy full-term deliveries with explicit documented donor consent.

SPEAKER_01 14:48

Okay, that covers the ethics part. What about the laboratory standards? The sources mention um CGMP and BSL2. What does that actually mean for the patient sitting in the chair?

SPEAKER_00 14:58

Aaron Powell It literally means the difference between a pharmaceutical grade environment and like a back office refrigerator.

SPEAKER_01 15:04

Okay, that's a big difference.

SPEAKER_00 15:05

Massive. Yeah. CGMP stands for current good manufacturing practice. It's a strict regulatory standard that ensures every single batch of cells is consistently produced and heavily controlled for quality.

SPEAKER_01 15:17

And BSL2?

SPEAKER_00 15:18

BSL2, or Biosafety Level 2, designates a laboratory that's built with specific airflow, containment, and sterilization protocols to handle human biological materials safely.

SPEAKER_01 15:27

So it's super clean.

SPEAKER_00 15:29

Extremely. Every batch undergoes rigorous identity, sterility, and viability checks before it ever reaches a patient. They are guaranteeing the cells are alive, and more importantly, that they are completely free of bacterial or fungal contamination.

SPEAKER_01 15:45

Which is completely non-negotiable when you are injecting biological material into a human being.

SPEAKER_00 15:50

Absolutely non-negotiable.

SPEAKER_01 15:52

Now, the sources also make a point to explicitly state what they do not use. They do not use embryonic stem cells, and they do not use pluripotent stem cells. Why is that distinction so important?

SPEAKER_00 16:03

Because pluripotent stem cells have the ability to differentiate into literally any cell type in the human body.

SPEAKER_01 16:09

Which sounds good, right?

SPEAKER_00 16:10

It sounds amazing in theory. But in clinical practice, it makes them highly unpredictable. If they aren't controlled perfectly, they can form tumors or unwanted tissue types.

SPEAKER_01 16:19

Oh wow. Okay.

SPEAKER_00 16:20

So by sticking strictly to multipotent MSCs from Wharton's jelly, Sirona cell is using cells that are naturally programmed to act as those immune-modulating site managers without the chaotic risk of unwanted tissue growth.

SPEAKER_01 16:33

Okay, so I want to ground this in reality for the listener. Let's say I am an international patient. I live in Australia, I've had Crohn's for a decade, I'm failing biologics, and I find Serona cell online. I can't just fly to Kuala Lumpur, walk in and demand an IV drip, right? Walk me through their actual clinical pathway.

SPEAKER_00 16:53

Right. You definitely cannot just walk in. It is a rigid, four-step, minimally invasive pathway. Step one. Step one is a comprehensive medical evaluation. You must provide your extensive medical history, recent endoscopic scan results, imaging, blood markers for inflammation, and your current medication list.

SPEAKER_01 17:12

They need the whole picture.

SPEAKER_00 17:13

Everything. Their medical team reviews all of this to determine if you are actually a safe candidate. They analyze your flare history, the presence of active fistulas or severe strictures, and your overall nutritional baseline.

SPEAKER_01 17:24

And I imagine this is where a lot of people get turned away. Because I mean, if my gut is severely strictured and completely blocked with thick scar tissue, stem cells aren't going to just dissolve a physical blockage.

SPEAKER_00 17:35

Exactly. They won't. If you have advanced structural damage that requires surgery, or if your disease is actually so mild that just optimizing your standard medication is a better route, their mandate is to transparently tell you that. Patient selection is everything.

SPEAKER_01 17:51

Okay. So let's say I'm accepted. What's step two?

SPEAKER_00 17:54

If you are accepted as a candidate, step two is cell preparation. The lab specialists saw and prepare your specific batch, running those final sterility and viability checks in the BSL2 lab we talked about.

SPEAKER_01 18:05

And step three is the actual administration. The sources note there is no open surgery involved.

SPEAKER_00 18:11

Correct. For a systemic disease like Crohn's, the MSCs are typically delivered via a simple IV infusion drip. The cells travel through the bloodstream and naturally home in on areas of high inflammation.

SPEAKER_01 18:21

Oh, they find it themselves.

SPEAKER_00 18:22

Yes. Now, if you are dealing with a localized structural issue like a perianal fistula, similar to the Edmeyer CD trial, they may use targeted localized injections directly into the tissues surrounding the fistula tract. The goal is always to minimize structural trauma to an already compromised gut.

SPEAKER_01 18:38

Which makes sense. And that leads to step four. So I get the infusion, I feel better, and I fly back home to Australia. But we already established Crohn's is a lifelong chronic condition. How on earth does a clinic in Malaysia know I haven't relapsed six months later?

SPEAKER_00 18:53

That is where step four, monitoring and follow-up, becomes critical. They don't just wave goodbye at the door.

SPEAKER_01 18:59

Good.

SPEAKER_00 19:00

They systematically track your symptom changes, your stool patterns, and your energy levels over the following months. And most importantly, they coordinate this follow-up data with your existing home gastroenterologist.

SPEAKER_01 19:11

Oh, they work with your local doctor.

SPEAKER_00 19:13

Exactly. The regenerative therapy must integrate into your wider ongoing care plan.

SPEAKER_01 19:18

So what does this all mean? When we look at this entire landscape, the chaotic, friendly fire of the immune system, the specific signaling power of MSCs, the intense reality of the clinical trials, and the rigorous safety protocols in Kuala Lumpur, it means that regenerative medicine is an adjunct. It's a highly sophisticated, deeply researched teammate, but it is not a replacement for your primary gastroenterology team. It sits beside standard care to provide heavy reinforcement when the usual breaks just aren't enough.

SPEAKER_00 19:49

It really is a paradigm shift in how we manage chronic disease. It is about offering a structured, scientifically validated auction that respects both the complexity of the human immune system and the daily reality of the patient. It requires rigorous safety standards, total transparency, and a commitment to long-term patient monitoring over quick one-time procedures.

SPEAKER_01 20:10

Now, before we wrap up this deep dive, there was one final, deeply fascinating detail buried in the sources that we just have to discuss: the exosome bonus.

SPEAKER_00 20:19

Ah, exosomes, yes. So CeronaCell also utilizes exosome therapy alongside their stem cell treatments. And exosomes are not cells themselves.

SPEAKER_01 20:28

What are they?

SPEAKER_00 20:28

They are microscopic extracellular vesicles. Essentially, they're tiny messenger packets that are naturally secreted by stem cells.

SPEAKER_01 20:35

I love the way the sources describe this. It's like little cellular text messages.

SPEAKER_00 20:38

That is the perfect way to visualize it. These messenger packets carry a concentrated payload of signaling proteins, growth factors, and genetic information. They travel through the body, enter other cells, and directly instruct them to calm down the inflammatory response and ramp up tissue repair.

SPEAKER_01 20:55

Wow.

SPEAKER_00 20:55

Yeah, so by introducing additional exosomes, you are massively amplifying the communication network that the stem cells are trying to establish inside the damaged gut tissue.

SPEAKER_01 21:05

It is completely mind-blowing. I mean, we started this deep dive talking about a faulty home security system, an alarm that wouldn't turn off, prompting the police to tear down the walls of the house. And standard medicine has spent decades trying to forcefully cut the wires to that alarm with harsh chemical suppressants.

SPEAKER_00 21:22

Right. But this raises an important question.

SPEAKER_01 21:24

Yeah.

SPEAKER_00 21:24

If exosomes in mesanchymal stem cells prove that true, lasting healing is fundamentally about communication, about delivering the precise microscopic messenger pack it's needed to teach our own panicked immune cells how to behave. Are we standing at the edge of an entirely new era in medicine?

SPEAKER_01 21:41

It really feels like it.

SPEAKER_00 21:42

An era where instead of forcing the body into submission with heavy systemic chemicals, we are finally learning how to remind the body how to feel itself simply by speaking its native cellular language.

SPEAKER_01 21:55

Aaron Powell And maybe, just maybe, by learning to speak that exact language, we can finally figure out the Right passcode to turn off that faulty alarm system for good. It's a wildly hopeful, incredibly complex thought to leave you with.

SPEAKER_00 22:08

It certainly is.

SPEAKER_01 22:08

For everyone listening, whether you are navigating a chronic condition yourself or just fascinated by the edge of medical science, thank you for exploring this with us. Keep questioning, keep digging into the science, and we'll see you on the next deep dive.